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ABSTRACT  
Background: Tuberculosis (TB) and human immune deficiency virus (HIV) infections 
are two major public health problems in many parts of the world .TB is the leading 
cause of morbidity and mortality among HIV-infected individuals. 
Objective: To assess incidence and predictors of tuberculosis among PLHIV in afar 
heath facilities, northeast Ethiopia 2015. 
Methods: A retrospective follow up study was conducted among 503 adult (age>15 
years) PLHIV who enrolled in HIV care clinic from July 1, 2010 to June 30, 2011. Ethical 
clearance was obtained from school of medicine. Data collected from patient records. 
Data checked for completeness and entered to EPI-INFO version 7 then exported to 
SPSS version 20 for further analysis. Bi-variate and multivariate Cox proportional model 
were fitted to investigate predictors. p value <0.05 in the multivariate Cox proportional 
hazards model independently associated with the outcome variable.  
 
Result: of all the 503 charts reviewed, 451 charts were included in the analysis. For a 
total of 1377.30 Person Years (PY) of observation, 119(26.38%) developed TB. The 
overall incidence density of TB was 8.6 cases per 100PY. Sixty-eight (57.14%) of TB 
developed at the first year of follow up. Past TB history (AHR=2.32, 95%CI=1.511-
3.573). Ambulatory and bedridden functional status at baseline (AHR=2.42, 
95%CI(1.05-5.59) ,(AHR=2.42 ,95%CI=(1.56-3.75). Baseline BMI<18.5kg/m2 
(AHR=1.621, 95 %CI =1.09-2.40).Not take IP (Isoniazid prophylaxis therapy) (AHR= 
6.96,95%CI=2.53-19.08). Baseline Hgb <12.5g/dl and Hgb <10 g/dl (AHR=2.00, 95% 
CI=1.08-3.71), (AHR= 2.54, 95%CI=1.57-4.11) respectively were predictors that 
associated for TB occurrence. 
Conclusion and recommendations: TB incidence in adult PLHIV remains high. Past 
TB history, Not receiving IPT, low BMI, low Hgb and unable to work was the most 
significant predictors for occurrence of TB. The high incidence of TB finding in this study 
call for an improved TB/HIV activity and scale up of IPT to reduce risk of TB is 
advisable. 
Key words: Afar, HIV, Incidence, tuberculosis, northeast 
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         1. INTRODUCTION  
1.1 Statement of the problem 
Tuberculosis (TB) is a chronic infectious disease caused by mycobacterium tuberculosis 
(MTB).It typically affects the lung but also can affect other parts of the body as well(1). 
TB and human immune deficiency virus (HIV) infections are the two leading public 
health problems in many parts of the world(2, 3). Since the beginning of the later 
pandemic, nearly 78 million people have contracted HIV and close to 39 million have 
died of AIDS causes. In 2013, an estimated 2.1 million people were newly infected with 
HIV. More- than two-thirds (70%) of all people with HIV, 24.7million, live in sub-Saharan 
Africa and 1.5 million people in the region become newly infected in 2013(3, 4). 
 Globally about a third of world’s population was estimated to be infected with tubercle 
bacilli and hence at risk of developing active TB disease(1). It ranks as the second 
leading cause of death from a single infectious agent, after HIV(2, 4). In 2013 globally 9 
million people develop incident cases of TB and 12 million prevalent TB cases and 1.5 
million people died from TB. The 22 high burden countries accounted for 82% of all 
estimated cases worldwide(4). 
Worldwide, TB was a leading cause of death among people living with HIV and HIV was 
the most potent risk factor for the development of tuberculosis. According to WHO 
report 2014, 1.1 million incident TB cases are among people living with HIV. In 2013, 
1.5 million people died from TB, including 360,000 among people who were HIV-
Positive. The prevalence of TB-HIV Co-infection is higher worldwide and 90% of these 
co-infected cases live in developing nations(4). Developing nations are the home of this 
deadly tied disease. Sub-Saharan Africa accounted for 79% of the burden of TB-HIV co 
infections, followed by South-East Asia (11%). In the African region that has the highest 
TB/HIV burden, three out of four TB patients knew their HIV status Globally,70%of the 
TB patients known to be living with HIV in 2013 were started on antiretroviral therapy 
(ART).In 2013, 5.5 million people enrolled in HIV care were screened for TB, up from 
4.1million in 2012. Of the people newly enrolled in HIV care in 2013, 0.6 million were 
provided with ionized preventive therapy(4-6). 
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Even though tuberculosis is the most commonly diagnosed opportunistic infection and 
disease in HIV infected individuals which can be curable and reduced with appropriate 
measure of therapy but hidden TB can hasten the progression of HIV(6). The presence 
of TB may affect individuals with HIV infection in numerous ways .TB increase T-cell 
replication and it increases HIV replication and it leads to increased viral load. TB 
facilitate occurrence of other opportunistic infections(7) .It also challenging to diagnose 
TB with HIV because the clinical manifestations of TB in HIV infected individuals are 
somewhat different. The life time risk of HIV infected individuals to develop TB is 20-37 
times greater than HIV negative individuals to develop active TB from the latent 
infection of mycobacterium tuberculosis(4, 8).  
The dangerous synergy affects all aspects of both diseases, from pathogenesis and the 
epidemiologic profile, to clinical presentation, treatment, and prevention(6). This synergy 
also impacts largely the management of individuals co-infected with this deadly disease 
related to pill burden ,drug to drug interaction ,increased adverse effect and immune 
reconstitution inflammatory syndrome(IRIS.As a result, TB  become the leading  
opportunistic infection that cause of death among  HIV infected people. This factors and 
late diagnosis of TB highly contribute to keep the mortality rate of TB very high among 
the co-infected people (6, 7).  
 The WHO has classified Ethiopia 7th among the 22 high burden countries with TB 
.According the WHO Global report 2013, Ethiopia had an estimated 200,000 TB cases 
in 2011 with an estimated incidence TB cases of 258/100,000 population. TB mortality 
rate is 18/100,000 and the prevalence of all forms TB is estimated to be 237/100,000. 
According to WHO Global report 2014, Ethiopia remains in the list of the country’s most 
heavily affected TB with prevalent cases of around 200,000 ,224/100,000 and incidence 
cases of 211per 100,000. Also Ethiopia is among countries having high TB and HIV co 
infection rate(5). There are more than1 million people living with HIV virus in the country 
and roughly about 40-70% of HIV patients in Ethiopia are co-infected with TB. This 
Synergy also impacts largely the co infected individual’s social, economical and healthy 
aspects than those patients with only HIV infection(4, 8). Moreover, TB and HIV co-
infection are associated with special diagnostic and therapeutic challenges and 
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constitute an immense burden on healthcare systems of heavily infected countries like 
Ethiopia.  
 
Great efforts have been made in line with millennium development goals (MDG) and 
post 2015 TB related programs to combat TB/HIV in the last two decades. However, 
this collaborative activity is not uniformly effective on all the different socio demographic 
variations and limited resources areas in nearly isolated setting .Also the burden is not 
equally distributed in various socio demographic setting and this unequivocal 
distribution demands a research to determine the incidence and to pick the potential 
predictors associated with TB in order to identify potential risks and to improve 
prevention service in the venerable groups. 
 
 Therefore, studying the incidence and predictors of TB among HIV infected people on 
the nearly isolated setting will have a great value to continue the collaborative activity to 
hit the deadly epidemic and to improve the health care system in taking appropriate 
action in identifying the predictors and alarming the partners and responsible body to 
give attention to the nearly isolated setting.  
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1.2. Literature review 
1.2.1. Incidence of TB among PLHIV 
 
Several studies conducted in different places of the world showed the synergic effect of 
TB and HIV among HIV infected patients. A large study conducted on  synergic(7) 
interaction between HIV and TB epidemics   showed that HIV-associated TB contributes 
substantially to the burden of TB-associated morbidity and mortality(9). HIV infection is 
the strongest known risk factor for TB. High HIV prevalence rates are significantly 
correlated with high TB incidence rate. Urban population growth escalates the HIV and 
TB Syndemic in developing countries. The association between poverty, urbanization, 
housing density, and TB incidence is highly related (7, 10). Globalization and increased 
population mobility have shaped the HIV-TB syndemic.  Individuals with a new 
diagnosis of TB are nearly 19 times more likely to be co infected with HIV than those 
without TB (0.8% HIV and 15% HIV prevalence in incident TB cases (11). Conversely, 
people living with HIV are 20 to 30 times more likely to develop TB than those without 
HIV.In developed nations the incident cases of TB was increased with the HIV epidemic 
on HIV infected patients. In developing country the synergic effect is worse than the 
developed nations (12). HIV affects and alters TB transmission, duration of 
infectiousness and progression of disease. Similarly, HIV increases the risk of 
progression to active TB in both primary and latent TB. For HIV-uninfected individuals 
with latent TB infection (LTBI), the life-time risk of developing active TB due to 
reactivation is 8 to10%. In contrast, this risk is approximately 10% per year for HIV-
infected persons(13). Other studies showed that, ART reduces the incidence of TB 
among HIV infected patients but it associated with risk of TB-IRIS, adverse effects, pill 
burden and disease progression (6, 14, 15).  
According to a retrospective cohort study in Israel, conducted among 6579 PLHIV 
reported between 1983 and 2010, corresponding to 55737 person-years, 384 (5.8%) 
developed tuberculosis. The overall tuberculosis incidence-density was 6.9 cases/1000 
person-years (95% CI 1.8–12.0). The cumulative tuberculosis-incidence among PLHIV 
in 2010 was 586 times higher than in HIV-negative individuals (3400 and 5.8 cases per 
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100000 populations, respectively). .Majority of cases were immigrants came from 
endemic countries(16). 
From studies done in Malaysia, related to TB/HIV revealed that there is a rise in the 
incidence of tuberculosis cases among HIV infected patients since 2011. Similarly, a 
two-year multi-centered study found that, the co-infection rate among patients was 
estimated about 7.7%and TB incidence rate was 1.8 cases per1000 PY. HIV patients 
had greater rates of pulmonary tuberculosis (68-79%) and lesser rates of extra 
pulmonary tuberculosis(17).  
A cohort study conducted among 908 Mexican participants PLHIV followed for a total of 
3032.7 person-years showed that, there were 59 (6.5%) cases of incident tuberculosis 
during follow up (1.95 cases per 100 person-years (95% CI= 1.51-2.50) (18) .similarly in 
a retrospective medical record based study conducted in Korea among total of 1,301 
HIV-infected patients observed between January 1998 and December 2010 revealed 
that, Eighty-four patients were diagnosed as having TB during the study period, seventy 
(5.4%) of patients were newly diagnosed during the study period with incidence rate of 
1.23 cases per 100 PY.  Initial CD4+ cell count <200 cells/μl at the time of enrollment 
was independently associated with an increased incidence of TB(19).  
A study conducted among household contacts in south Africa showed that, the overall 
TB incidence rate was 1.3 per 100 person years (95% CI= 0.9-1.9/100py) and TB 
incidence for individuals who were HIV-infected and HIV sero-negative at baseline was 
5.4/100py (95%= CI 2.9-9.0/100py) and 0.7/100py (95% CI= 0.3-1.4/100py), 
respectively.(20). 
 A 2 year prospective study done in Tanzania among both ART and Pre-ART groups of 
67, 686 patients 7602 patients were diagnosed with active TB. The TB incidence rate 
was 7.9 [95% confidence interval (95% CI= 7.6-8.2] per 100 person-years prior to ART 
initiation, and 4.4 (95% CI= 4.2-4.4) per 100 person-years for patients receiving ART. 
Risk factors for incident TB included being male, having low BMI or middle upper arm 
circumference, lower CD4 cell count and advanced WHO disease stage(21). Similarly 
an eight year follow up study done in sub- Saharan  Africa among 7114 HIV positive 
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patients enrolled, During follow-up, 421 incident tuberculosis cases were notified with an 
estimated incidence of 3.6 per 100 P-Y [95% (CI= 3.26-3.97]. The incidence rate varied 
over time and increased significantly from 2.96 to 43.98 cases per 100 p-y. Poor clinical 
condition at baseline (Hazard Ratio (HR) 3.89, 95% CI =2.87-5.28), WHO clinical stage 
3 or 4 (HR 2.48, 95% CI= 1.88-3.26), being anti-retroviral naive (HR 2.97, 95% CI= 
2.25-3.94 (22). 
Like other studies in Africa studies conducted in Ethiopia among PLHIV revealed that 
incidence of TB was high. According to retrospective cohort study done in northwest 
Ethiopia, showed that incidence of   TB were 7.9 cases per 100 PY. The median time 
for development of incident TB during the follow-up was 9.5 months (IQR, 5.5-16.5 
months. Majority of the incident TB occurred within the first year of follow up(23).  
Similarly, studies done in west part of Ethiopia found that incidence rate of TB during 
follow up among 588 patients on pre-ART care was an overall incidence of 3.78 cases 
per 100 PY. The incidence rate  was higher among non-IPT users( 5.06 per 100 PY but 
it was 2.22 per 100 PY in IPT user group (24) .Likewise , studies from Assella  hospital 
revealed that, incidence of TB among HIV positive individuals on HAART was 3.73 
cases of TB per 100 person year while it was 7.02/100 PY among individuals on pre 
HAART follow up(25). 
1.2.2 Predictors of tuberculosis among adult PLHIV 
 There are various reported risk factors for the development of TB among adult PLHIV. 
These factors can be classified and described as socio demographic, clinical, treatment 
related and nutrition related factors and like. Similar to HIV negative people with TB 
cases adult males predominate in having TB with HIV in studies done in previous 
studies (16, 19, 26). Still there are multiple studies which showed to the contrary(18, 
27). Younger age was also found to be a common determinant factor as compared to 
those above 40 years of age(16, 18). But few studies found that advanced age was risk 
factor for developing it (19, 27). Considering residence, urban residents were found to 
be more risk factor for TB among HIV infected patients(28). Some behavioral factors 
(substance use) like alcoholism, cigarette smoking was associated with treatment failure 
among HIV infected patients indirectly increased the risk of TB among the HIV infected 
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patients (16, 17). Also, previous history of TB found to be a determinant factor for TB 
development among HIV infected patients((16). As TB is an opportunistic disease, low 
CD4 count and advanced WHO clinical stage at base line were highly associated with 
development of TB .Low CD4 count was one of the strongest determinant factor among 
this group(17, 23, 26).   
In addition, other risk factors like diabetes mellitus, chronic kidney disease, functional 
status and presence of other opportunistic were significantly associated with 
reactivation and development of active TB among HIV infected people(16, 28, 29).  
Another study revealed that having a low BMI is a risk for development of TB among 
HIV patients(21). In a seven year study conducted among adult PLHIV in Dares 
Salaam, Tanzania, showed that 976 HIV patients enrolled to the follow up 9.4% were 
develop active TB throughout the prospective follow up. The study revealed that 
baseline BMI, Year 1 BMI and change in BMI from baseline to Year 1 were all 
significantly and independently associated with the risk of developing TB during 
prospective follow-up. Patients with a baseline BMI < 17 kg/m2 had a greater risk of 
developing TB during prospective follow-up (HR 3.72, 95%CI =1.16–12.0, P= 0.028. 
Also, patients whose BMI fell by >0.5 kg/m2 from baseline to Year 1 had a greater risk of 
developing TB (HR 2.03, 95%CI 1.29–3.20, P= 0.002. likewise, a cohort study in 
Uganda revealed that hemoglobin of ≤10 mg/dl, BMI ≤15.5 kg/m2, and opportunistic 
infections other than TB were  significant risk factors for the development of TB among 
this group(20, 21, 30-33).  
 Different studies also, showed that use of IPT, ART and CPT reduces the risk of active 
TB in HIV-infected individuals., treatment of latent TB infection (LTBI) in HIV-infected 
individuals helps to reduced the risk of active TB by 32% (risk ratio (RR) 0.68; 95% 
confidence interval (CI= 0.54 - 0.85)(24, 34, 35).The use of ART in HIV-infected adults 
also magnificently reduces the incidence of TB. Also, patients starting ART earlier, at 
higher CD4 cell counts, have a 2-fold lower risk of TB compared with those initiating 
ART at lower CD4 cell counts(29, 36). Similar result was revealed from a in south Africa 
with, a 37% reduction in the risk of TB was evident in individuals receiving IPT and ART 
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compared with patients receiving ART only (RR 0.63)(22). As part of a comprehensive 
HIV Care package, all HIV and TB clinics should benefited from co-trimoxazole 
prophylaxis concurrent use with other medications like HAART, anti-tuberculosis drugs 
and drugs that treat other opportunistic infections by giving especial attention to signs of 
side effects and adherence(37, 38).  
Studies conducted in Ethiopia revealed that, several determinant factors associated for 
incidence of TB among HIV infected people. In almost all studies young age groups 
were the predominant risk group to develop incident tuberculosis (39). Inline to studies 
in Africa females and urban residents were more risk to develop TB than males and 
rural residents (24, 25). HIV infected individuals who had not attended formal education 
were found to be 4.5 times more likely to develop TB than those who attended formal 
education, OR = 4.55, 95% CI(2.09- 9.90)(39).Low CD4 cell count (<200cell/mm3) and 
advanced WHO clinical stages and unable to work in functional status were 
independently  associated to develop active TB than those HIV infected individuals with 
CD4 count of  >500cells/ mm3, early WHO clinical stages  and able to work(23, 40). 
Having low hemoglobin level < 10mg/d , OR = 2.96, 95% CI= (1.28, 6.80),and Having 
BMI <18.5 kg/ m2  were found to be significantly associated with TB infection, OR = 
3.80, 95% CI =2.39,6.08)(40).Patients with diabetic mellitus and being pre-ART  were 
more likely infected with TB, OR = 3.53, 95% CI =1.55, 8.07) but  being on INH 
preventive therapy (IPT) treatment was marginally associated with tuberculosis co-
infection(39, 40) . in the contrary IPT was independently associated with incidence of 
TB(24). 
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 Figure1. Conceptual frame work of incidence of TB among Adult PLHIV (this 
developed from variable in the Literature review) 
Socio demographic                           
factors  
 Age  
 Sex   
 Residence 
 Educational 
status  
 Substance use 
  
 
 
 
 
 
 
 
Clinical characteristics  
 WHO clinical stage 
 CD4+ count  
 History of TB 
 History of chronic illness  
 History of other OI’s 
 Functional status  
 BMI 
 Hgb level  
 
 
 
 Treatment related 
characteristics   
 CPT use 
 IPT use 
 HAART status 
 Initial HAART 
regimen 
 Regimen change 
 Adherence   
 
 
 
 Incident TB  
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1.3. Justification of the study  
Tuberculosis is the main cause of morbidity and mortality among HIV infected people. It 
also enhances the burden of other opportunistic infections. TB co- infection in HIV 
infected individuals causes several problems on the patient like adverse effect of 
medication, pill burden and drug to drug interaction with the pre existing HAART and 
other OI’s medications. 
  In the study setting no study has been conducted. Therefore it will enrich the existing 
level of evidence by closing the place gap in information and it will help policy makers 
and stake holders to strengthen the TB/HIV prevention and control programs in the set 
up. Moreover, it helps to show the gab to the partners and responsible body working on 
the TB/HIV collaborative activity. 
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                                      2. OBJECTIVE  
2.1 General Objective 
The aim of this study is to assess the incidence and predictors of tuberculosis among 
adult people living with HIV in Afar public health facilities, northeast Ethiopia 2015. 
 
2.2 Specific Objectives  
 To determine incidence rate of tuberculosis among adult people living with HIV in 
afar public health facilities, northeast Ethiopia 2015. 
 To identify predictors of tuberculosis occurrence among adult people living with 
HIV in afar public health facilities, northeast Ethiopia 2015. 
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  3. METHODS  
 3.1 Study design  
Institution based retrospective cohort follow-up study design was employed to assess 
the incidence and predictors of tuberculosis among adult people living with HIV.   
3.2 Study area and period 
 Data was collected from May to Jun, 2015 in Afar national regional state selected 
health facilities. Afar is located in the North-eastern part of Ethiopia. The region has a 
population of 1,678,000 only 289,000 population live in urban and semi urban area(41). 
Administratively the region consists of five administrative zones with 32 districts with 28 
urban and 401 rural counties (Kebeles). The capital city of the region (Samara) is 
located 536 km away from Addis Ababa.  In Afar there are four hospitals, 40 health 
centers, 270 health posts and 15 private clinics delivering health services for the people 
living in the region. HIV care service introduced in the region in 2006/7. According 
recent report 15 health institutions provide HIV chronic care and support service for 
around 4,000 PLHIV.  The study sites selected based on their number of client follow 
and presence of TB and HIV follow up clinic. Based on this, the study was focused on 
two health centers (Awash, and Samara ), Asayta hospital, Abala hospital and the only 
general hospital (Dubti) in the region. These health institutions provide chronic HIV care 
and follow up for about 70% of patients living with HIV in the region.                     
3.3 Source population 
The source population of the study was all adults PLHIV who had enrolled to chronic 
HIV care and support program in Afar health facilities. 
3.4 study population 
The study population was those adults PLHIV who are enrolled to chronic HIV care from 
July1, 2010 to June 30, 2011 in afar public health facilities (Dubti hospital, Asayta 
hospital, Abala hospital, and Awash and Samara health center. 
 
13 
 
3.5 Inclusion and exclusion criteria 
Inclusion criteria:  
 All adult PLHIV who enrolled newly in to chronic adult HIV care clinic from July 1, 
2010 to June 30, 2011. 
Exclusion criteria: 
 PLHIV on HIV care clinic with incomplete information (date of enrollment, 
baseline CD4 count and transfer in patients and patients with TB in the last 3 
month was excluded.  
3.6 sample size 
To determine the sample size for incidence of TB among HIV infected people single 
population proportion formula assuming 95% confidence interval (CI) and 5% margin of 
error (d) will be used. Considering prevalence of TB among HIV infected patients to be 
13% from the national figure but according to studies done in Jimma the prevalence is 
17%, then(42).  
n=initial sample size =      
                                            (    ) 
 (    )
  
        
                                            = (1.96)2(0.17) (0.83)/(0.05)2       
                                           =217 
 To determine the sample size for the second objective, two proportion population 
formula will be employed .Several studies indicated that base line CD4 ,WHO clinical 
stage and BMI are the best predictors of incident TB among HIV infected patients. 
Based on this assumption using EPI Info stata calcu  sample size will be determined at 
95% CI ,80% power of test  will be calculated for the key predictors from the previous 
studies(CD4 count <100,WHO clinical stage III or IV and BMI <18.5 )(21, 40). 
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Table 1: sample size calculation 
 
No  Key predictors  Assumption  Odds 
ratio/hazard ratio 
Sample size  
1 Advanced WHO 
stage  
At 95% CI 
and power 
80% 
 2.0 9 (1.33, 
3.28)    
          291 
2 Baseline 
CD4>200cell/ml 
At 95% CI 
and power 
80% 
2.35(1.23, 4.48)               290 
3 Baseline BMI 
<18.5 
At 95% CI 
and power 
80% 
3.85(2.39, 6.08)             98 
    
 As shown on the table sample size for similar calculations was employed for other 
exposure variables (educational status, age, sex, past TB ) and the sample size 
calculated for predictors is greater than the sample size estimated on proportion .so, the 
two population proportion sample size was maximum number 291 and it will be taken as 
the final sample size for this the study; by considering 3.3% (40) of expected incomplete 
records the final sample size  301. 
But for this study for sake of better statistical power, all the records 503 were reviewed.  
3.7 sampling procedure 
All adult people living with HIV who was enrolled from July 1, 2010 to June 30, 2011 to 
adult chronic care clinics of the selected health facilities   was included in the study and 
looking their five year follow up till May15, 2015. 
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Figure 2. Schematic presentation of the selected health facilities 
The total sample size was taken from the above five health facilities. All the study 
subjects found during data collection included in the study.  
 
3.8 Data collection method 
Available information on the patient chart was observed and suitable data extraction 
format was prepared in English. Subsequently, the data was collected by four diploma 
nurses and two BSc nurses who had ART training using the data collection format from 
the patient records. Data clerk of each health facility and case managers assisted the 
data collators by identifying the charts. Charts were retrieved by using the patient 
medical record number and ART registration number which is found on the data base of 
the health facilities. 
Dubti general 
hospital  
n=205 
Asyita 
hospital 
n= 117 
Abala Hospital 
n=66 
Samara HC 
n=39 
Total sample 
size n=503 
 
 
n 
Awash HC 
n=76 
 
All patients in the five health institutions  
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3.9 Data quality assurance 
Quality of data was maintained by recruiting data collectors and supervisors who had 
ART training. One and half day comprehensive training  was given for data collectors 
and supervisors prior to actual data collection on the objective of the study and how to  
collect data from the charts using the format prepared for the study purpose. Concise 
information about the variables on the format and patient charts .Data collection tool 
was pre tested for consistency of review tools and completeness of understanding the 
review tools and completeness of data items on 10% charts at logia health center. The 
retrieval process was closely monitored by the two supervisors and by the principal 
investigators on daily bases throughout the data collection period .Completed forms 
were checked regularly for completeness of information and any slit immediately 
identified and correction measure was taken. 
3.10 study variables 
3.10.1 Dependent variable  
 incidence  of TB   
3.10.2 Independent variable 
Socio demographic characteristics: 
 Age 
  Sex  
 Residence 
 Educational status 
  Substance use  
Clinical factors  
 WHO clinical stage 
  CD4 count 
 Chronic illness  
 Previous TB history  
 Functional status 
 other opportunistic infection 
 BMI 
 Hemoglobin level 
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Follow up and treatment related characteristics:  
 ART status 
 Initial  HAART regimen 
  Initial regimen change  
 Co-trimaxazole prophylaxis therapy   
 INH  prophylaxis 
 Adherence   
3.11. Operational definition 
Chronic illness: - Non AIDS defining chronic illness like DM, Kidney disease and 
malignance   
CPT prophylaxis: - A patient who took co-trimaxazole for greater than 1 month for 
prophylaxis purpose. 
Event or incident TB:-any form of TB that diagnosed clinically or radigraphicaly or 
laboratory confirmed or patients who start anti TB empirically after enrollment. 
INH Prophylaxis:-A patient who took INH alone for a purpose of TB prevention more 
than 3 month 
Substance use:-In this study substance use is considered as any substance use 
recorded in the intake form of the patient chart    
Censored :-participants, who did not develop the event till the end of the study or died, 
transfer out or drop out from follow up without having the event. 
3.12 Data processing and analysis 
After the data checked and cleaned for its completeness, it was entered to EPI-INFO 
version 7 and exported to SPSS version 20 for further analysis. Statistical   summary 
was applied to describe socio demographic, clinical and follow up variables. Magnitude 
will be calculated and described by frequency and tables. Incidence density rate was 
calculated for the study period. Kaplan Meier was used to compare different categories 
of survival probability respectively. Bi-variable and multivariate   Cox regression model 
was used to identify the predictors.  Variables with value of p <0.2 in the bi-variable 
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analysis was candidate for multivariate proportional hazard model.95% CI of hazard 
ratio was computed .variables having p value <0.05 in the multivariate Cox proportional 
hazards model was taken as significant and independently associated with the outcome 
variable. The model fitness was checked with graphical and residual tests. 
3.13 Dissemination of finding  
 Finding of the study was submitted to department of internal medicine, college of 
medicine and health science, university of Gondar. It will also present to University of 
Gondar. The dissemination also goes to afar regional health office, Dubti hospital, 
Asayta hospital, Abala hospital, Awash, and Samara health center and other 
stakeholders. 
 In addition possible effort will be made to present the findings of the study in different 
professional meetings/conferences and the manuscript will be sent to journals for 
publication.  
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3.14 Ethical consideration 
Ethical Clarence was obtained from the IRB of the institute of school of medicine, 
university of Gondar. Permission was obtained from the ARHO and written permission 
letter was sent to each health facilities to conduct this research. Unique identification 
information was not collected on the extraction format and for all information taken from 
the chart confidentiality and security issue was maintained. The collected information 
was only used for the study purpose. 
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       4. RESULTS    
      4.1 Baseline socio-demographic characteristics of PLHIV 
A total of 503 records of PLHIV who were enrolled from July 1, 2010 to June 30, 2011 
were reviewed. Fifty two (10.44%) of them were not included in the analysis due to 
incomplete information. Among the 451 patients remaining in the analysis the mean age 
(SD) was 32.55+7.48) and almost two third 297(65.9%) of them were below the age of 
35 years. The data were collected from five health institutions urban residents were 410 
(90.9%).More than half 267(59.2%) of PLHIV were females and 275 (61%) were also 
Muslim in religion. 
 
At most half 234(51.9%) of patients were self employed. One hundred thirty (28.8%) 
patients recorded as substance users either of drugs 20% or tobacco 3.1% or alcohol 
5.7% .Majority, 374(93.1%) of the patients were living in family size of 1-5.Almost half 
212(47%) of the patients never went to formal education. More than two third (68.1%) of 
the patients were currently or formerly married.  
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Table 2 Socio -demographic characteristics of PLHIV enrolled to chronic HIV care 
at Afar health facilities, northeast Ethiopia June 30, 2015, 
Characteristics                                           Frequency  (n=451                                    Percent% 
    Age 
  15-24 55         12.2 
 25-34 242         53.7 
 35-44 119        26.4 
 45 and above 35        7.8 
 Sex 
  Male 184         40.8 
Female 267          59.2 
Marital status 
  never married 144          31.9 
Married 200        44.3 
divorced/separated 77       17.1 
Widowed 30        6.7 
Residence 
  Urban 410       90.9 
Rural 41        9.1 
Religion  
  Muslim 275        61.0 
Orthodox 165        36.6 
Others 11         2.4 
      Educational status 
  no formal education 212         47.0 
Primary 177       39.2 
secondary and above 62     13.7 
     Family size 
 1-3 216      47.9 
4-5 159      35.3 
>5 76      16.9 
Occupational status 
 self employed 234       51.9 
 government employed 45      10.0 
 no employment 172      38.1 
Substance Use 
  Users 130         28.8 
 non users 321         71.2 
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4.2. Baseline clinical and HIV related follow up characteristics of PLHIV                       
 
From the total of 451 study participants (53.4%) had a baseline WHO clinical stage III 
and IV. Majority 366(81.2%) of Participants were enrolled with working functional status. 
Participants had baseline median CD4 cell count of 285 cell/ml(IQR178-383) at 
enrollment. Almost half 218(48.3%) of the participants were enrolled with BMI <18.5.  
270(59.9%) study subjects had a baseline Hgb<12.5. During the follow up majority 
413(91.8%) of the participants provided with CPT but only 94(20.8%) of the participants 
received IPT. 
 
The eligibility criteria for the initiation of HAART was mainly WHO clinical stage 
183(40.6%) and both WHO clinical stage and CD4 cell count 167(37 %.) respectively. 
The initial regimen frequently prescribed for the study participants were  a combination 
of TDF,3TC and EFV 170(37.7%)followed with AZT,3TC and EFV110(24.4%) . Ninety 
six (21.3%) of participants changed their initial regimen.92(95.8% ) of change was 
substitution and only 4(4.2%) patients switched to second line .majority of the drug 
changes was made following the development of side effect 50(52.08%) and 29(30.2%) 
changes was following development of TB.  
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Table 3. Baseline clinical and HIV related follow up characteristics of PLWHA in 
Afar  health facilities north east Ethiopia 2015. 
     Characteristics Number(n=451  Percent  
 Past TB  
       Yes  74      16.4 
        No  377      83.6 
OI* 
 Yes  34       7.5 
 No  417      92.5 
Chronic illness  
 Yes  35     7.8 
 No  416     92.8 
Base line functional status  
Working  366     81.2 
Ambulatory and bedridden 85     18.8 
 BMI  
  <18.5 218      48.3 
  ≥18.5 203     45.0 
WHO clinical stage 
           I 62      13.7 
          II 138     32.8 
          III 172     38.1 
          IV 69      15.3 
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Table 3. Baseline clinical and HIV related follow up characteristics of PLHIV in 
Afar health facilities, northeast Ethiopia 2015 continued …… 
Hgb level  
<10 56     12.4 
10-12.49 214     47.5 
≥12.5 181     40.1 
CD4 count  
 <100 44      9.8 
   100-200 124      27.5 
  200-349 125      27.7 
 ≥350 158      35.0 
Initial regimen 
  d4t-3TC-NVP 65      14.4 
    AZT-3TC-EFV 89       19.7 
  AZT-3TC-NVP 110      24.4 
  TDF-3TC-EFV 170      37.7 
Others♣
 
17      3.8 
Eligibility criteria  
  CD4 cell count  62      13.7 
  WHO clinical stage  183      40.7 
CD4 count and WHO stage  167      37.0 
   Unrecorded  39      8.6 
CPT use 
  Yes 413      91.6 
   No 38      8.4 
   IPT use  
  Yes  94      20.8 
  No  357      79.2 
Did regimen changed 
       Yes  96       21.3 
       No 355        78.7 
Type of the changed regimen    
 First line  92          20.4 
 Second line 4         0.9 
Reason for change  
Tuberculosis  29         6.4 
Side effect  50        11. 
Failure  4         0.9 
Others♣♣ 13          2.9 
 Adherence  
Consistent 351          77.8 
Inconsistent  100           22.2 
 
OI*=other than TB, others♣, d4t-3TC-EFV, TDF-3TC-NVP&ABC-3TC-EFV 
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4.3 TB incidence rate  
 
Four hundred fifty one study participants were followed for different periods in the follow 
up for a total of 1377.303 Person Years of observation. One hundred nineteen (26.4%) 
of participants develop TB while on follow up and 332 individuals censored (40 patients 
transferred out, 13 patients died, 21 drop out and 258 remained till end of follow up. 
Therefore, the overall TB incidence rate on the follow up period calculated using Person 
–year of follow up was 8.64 cases per 100 Person Years. Study participants stayed in 
the follow up for a minimum of 0.03 month and maximum of 58.83 months. The median 
observation period was 46.74 months [IQR=15.95-52.42 months].The median survival 
time is 54.00 month. Among the TB cases occurred in the follow up period 67(56.3% 
were females. Majority 91(76.47%) of the cases were pulmonary TB. Forty six (38.6%) 
of incident TB occurred within the first months of follow up and 68(57.14%) of incident 
TB cases occurred within the first year of follow up. 
Incident of TB is more common in urban105 (88%) of cases than the rural setting and in 
family size of >5 households. 
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 Table 4: Incidence of TB and socio demographic characteristics of the study participants in Afar 
health facilities, northeast Ethiopia 2015 
Characteristics                TB status  Total  
Censored 
(n=332 
Event of 
TB(n=119 
  Age  15-24  41(9.1% 
   
14(3.1% 55(12.2%  
25-34 179(39.7% 
   
63(14.0% 242(53.7% 
35-44 89(19.7%  30(6.7% 119(26.4% 
≥45 23(5.1% 
   
12(2.7% 35(7.8% 
Sex  
Male 132(29.3%) 52(11.5% 184(40.8% 
Female  200(44.3% 67(14.9% 267(59.2% 
Residence  Urban  305(67.6% 105(23.3% 410(90.9% 
Rural  27(6.0% 
  
14(3.1% 41(9.1% 
 Marital status  Never married  114(25.3% 
   
30(6.7% 144(31.9% 
 Married 148(32.8% 
   
52(11.5% 200(44.3% 
Divorced/separated  47(10.4% 
  
30(6.7% 77(17.1% 
Widowed  23(5.1% 
  
7(1.6% 30(6.7% 
Educational level 
    No formal education 157(34.8% 55(12.2%    212(47% 
     Primary 128(28.4% 49    177(39.3 
    Secondary and above 47(10.4 15(1.1%      62(13.7 
Occupational status  
    Self employed* 175(38.8% 
  
59(13.1%
  
234(51.9% 
    Government employed  36(8.0% 
   
9(2.1% 45(10.1% 
     No employment  121(26.8% 
  
51(11.3%
  
172(38.1% 
  Family size  
   1-3 165(36.6%  51(11.3%
  
216(47.9%
  
27 
 
   4-5 116(25.7% 
  
43(9.5% 159(35.3%
  
  >5 51(11.3% 
 
25(5.5% 76(16.9% 
Substance use  
    User  88(19.5%  42(9.3% 130(28.8% 
   Non user  244(54.1% 
  
77(17.1% 321(71.2%
  
    Religion  
  Muslim  205(45.5%) 
  
70(15.5%
  
275(61.0% 
  Orthodox  118(26.2% 
   
47(10.4% 165(36.6% 
  Others * 9(2.0%  
  
2(0.4% 11(2.4% 
*others =protestant, catholic … 
*self employed =Merchant, house wife, daily laborer  
 
4.4. Incidence of TB with PLHIV and their baseline clinical and follow up 
characteristics in Afar health facilities, northeast Ethiopia 2015. 
 
From the study participants who developed incident TB 41(34.5%) of them had history 
of previous TB or treatment history and 47(39.5%) of them were either ambulatory or 
bedridden at enrollment. Majority 115(96.6%) of the incident cases of patients not 
provided with INH prophylactic therapy. Ninety five (79.9%) of participants with incident 
cases of TB were enrolled with Hgb level below12.5g/dl. 
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Table 5Incidence of TB and clinical and follow up characteristics of the study 
participants in Afar health facilities, northeast Ethiopia 2015 
Characteristics Categories                 TB status  Total  
Censored 
(n=322) 
event of 
TB(119) 
 Past TB  Yes  33 41     74 
No  299 78     377 
OI* Yes  15 19 34 
No  317 100 417 
Chronic illness  Yes  24 11 35 
No  308 108 416 
Baseline 
functional status 
Working  294 72 366 
Ambulatory  35 39 74 
Bedridden  3 8 11 
Baseline BMI <18.5 143 75 218 
≥18.5 161 42 203 
WHO clinical 
stage 
I 55 7 62 
II 119 29 138 
III 113 59 172 
IV 45 24 69 
Baseline Hgb <10 33 23 56 
10-12.49 142 72 224 
≥12.5 157 24 181 
 
CD4cell count  
<100 22 22 44 
100-200 84 40 124 
201-349 96 29 125 
≥350 130 28 158 
 
 
Initial regimen  
d4t-3TC-
NVP 
51 14 65 
AZT-3TC-
EFV 
69 20 89 
AZT-3TC-
NVP 
82 28 110 
TDF-3TC-
EFV 
118 52 170 
Others* 12 5 17 
CPT use Yes  305 108 413 
No  27 11 38 
IPT Yes 90 4 94 
No  242 115 357 
Adherence  Consistent  261 90 351 
Inconsistent  71 29 100 
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Test of equality for survival distribution for the different levels of the different categories 
was performed with Kaplan Meier using the long rank test.  Association of difference 
was observed among the explanatory variables like BMI and IPT. 
Baseline BMI had a significant difference for tuberculosis –free survival as compared for 
people living with HIV. BMI <18.5 kg/m2 had low TB free survival as compared to those  
Figure 3 TB free survival probability with BMI among PLHIV in Afar health institutions northeast, 
Ethiopia July, 2010 –May 2015 
With BMI >18.5 kg/m2 with the overall comparison result long rank of p-value p<0.002 
and for the IPT was p<0.0001 which shows significant difference of TB free survival 
among patients provided with IPT. 
 
 
 
 
 
 
 
 
 
 
Figure 4. TB free survival probability with IPT among PLHIV in Afar health 
institutions northeast, Ethiopia July, 2010 –May 2015 
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4.4 Predictors of tuberculosis in Cox survival analysis 
In a bi-variable Cox regression analysis predictors with p<0.2 value was candidate for 
multivariate analysis. Eleven variables were significant associated in the Bi variable 
analysis this were CD4 cell count, WHO clinical stage, substance use, marital status ,OI 
,IPT, past TB history, BMI , Hgb ,functional status and family size were included in the 
multivariate analysis. The Enter and forward method was used in the multivariate 
analysis to see output value of the variables showed significance in bivariate analysis. 
Past TB history, baseline fictional status, baseline hemoglobin, baseline BMI and IPT 
were found statistically significant with having   value of p<0.05 in multivariate analysis. 
According to the Cox multivariate analysis HIV patients who had history of TB at 
enrollment were 2.32 times risky to develop TB at a time than those who had no past 
TB history (AHR=2.32, 95%CI=. 2.324(1.511-3.573).Patients enrolled to care with 
baseline functional status of  bed redden and ambulatory  were 2.42  times more prone 
to develop TB at any follow up time than those enrolled with working  functional status 
(AHR=2.42,95%CI(1.05-5.59) ,(AHR=2.42 ,95%CI=(1.56-3.75) respectively. Similarly, 
HIV patients having baseline BMI<18.5kg/m2 were1.62 times higher risky to get TB at 
any time than those with having BMI≥18.5kg/m2 at baseline (AHR=1.621, 95 %CI (1.09-
2.40).HIV patient who did not take IPT were 6.96 times more likely to acquire TB at any 
time compared to those who taken IPT(AHR= 6.96,95%CI(2.53-19.08).in addition 
,People living with HIV enrolled with baseline Hgb <12.5g/dl were 2.54 times more to 
develop TB at certain time than those having Hgb  above 12.5g/dl respectively 
(AHR=2.00 ,95%(1.08-3.71)  (AHR=  2.54,95%CI(1.57-4.11).  
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Table 6. Predictors of TB among PLHIV in Afar health facilities north east Ethiopia 2015 using Bi- 
variate  and multivariable Cox regression 
Explanatory variable           Number                                 
 
Marital status Censored 
(n=322 ) 
Event of 
TB(n=119) 
CHR,95%CI   AHR,95%CI   
Never married 114 30 1 1 
Married  148 52 .942(.41-2.14)* 1.16(.69-1.94) 
Divorced/separated  47 30 1.15(.52-2.53)*
  
1.31(.76-2.28) 
 
Widowed  23 7 1.90(.83-4.32)* 
 
1.55(.63-3.79) 
 
Family size 
1-3 165  51             1 1 
4-5 116 
  
43 .718(.83-1.16)* 1.33(.85-2.08) 
 
>5 51 25 .44(.50-1.36)* 1.54(.90-2.63)  
 
Opportunistic infection  
       Yes  15 19 2.61(1.60-4.27)*
  
1.270(.72-2.22) 
       No  317 100 1.00 1.00 
 Baseline Functional status 
    Working  294 72 1.00 1.00 
Ambulatory and 
bedridden 
38 47 .199(.096-.414)* 2.42(1.56-3.75)** 
BMI 
<18.5 143 75 1.80(1.23-2.63)* 1.62(1.09-2.39)** 
 
≥18.5 161 42 1 1 
WHO clinical stage 
                 I 55 39 1 1 
                II 119 29 .280(.121-.651)* 1.32(.57-3.06) 
               III 113 59 .489(.285,.840)* 1.90 (.84-4.29) 
 
               IV 45 24 1.00(.628,1.621)* 1.91(.78-4.65) 
 
   Hgb 
    <10 33 23 4.12(2.32-7.32)*  2.00(1.08-3.71)** 
  10-12.49 142 72 2.97(1.87-4.71)* 2.54(1.57-4.11)** 
 
    ≥12.5 157 24 1 1 
CD4 cell count  
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 *p-value <0.2, **p-value<0.05 in multivariate. ♣=p-value <0.2 
       ***p-value <0.001 in multivariate, 1=reference category  
Global test of proportional hazard assumption for predictors fitted to Cox proportional hazard  model was not significant  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Predictors of TB among PLHIV in Afar health facilities north east Ethiopia 
2015 using Bi- variate and multivariable Cox regression result continued. 
 
     <100 22 22 4.12(2.35-7.22)* 1.33(.68-2.61) 
      100-200 84 40 2.13(1.31-3.46)* 1.56(.89-2.73) 
      201-349 96 29 1.44(.85-2.42)* .93(.535-1.62) 
       ≥350 130 28       1 1 
IPT Use  
      Yes  90    4             1 1 
       No  242 115 .106(.03-.28)  6.96(2.53,19.08)*** 
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5. DISCUSSION   
It is universally acknowledged fact that HIV infection increases the incidence of 
tuberculosis. TB and HIV remains as major public health problems in many parts of the 
world. The fact that, Ethiopia is among the TB high burden countries with an estimated 
annual incidence of 211case per 100,000 populations and with prevalence of 224 cases 
per 100,000(4).TB is the most common cause of morbidity and mortality among 
PLHIV.HIV infected individuals 20-37 times greater risk to develop TB in life time 
compared to non infected individuals(7, 8). 
 
This study tried to assess the overall incidence of TB among the participants for the 
entire follow up period. It was found to be 8.64 cases per 100 person years. This finding 
was consistent with studies conducted in Ethiopia which founds (7cases /100 PY and 
7.9 cases per/100 PY)(23, 25). It also aggresses with findings from Tanzania7.9 (95% 
CI), 7.6-8.2] per 100 and Sub-Saharan Africa (21, 22). However, it was high as 
compared to studies conducted in Korea, Israel and Malaysia (16, 17, 19). This could be 
explained by the fact that these countries might have better preventive, diagnostic and 
treatment setups and strategies for controlling TB in contrast this study was done in a 
high TB burden country and scarce resources might contribute for this high result. Low 
health care coverage and late enrollment to health care facilities might contribute for this 
finding. This could be also explained with progression of the latent infection to active TB 
after initiation of HIV chronic care with late presentation of patients to health facility. The 
patient might get new infection or IRIS after initiation of HAART and other HIV related 
services. IRIS associated TB was commonly seen within the first 6 months after 
initiation of HAART (15).  
 
In different studies multiple predictors can predict the incidence of TB among PLHIV on 
HAART and Pre HAART era. Our study found that   past TB treatment history, non use 
of IPT, baseline functional status of bedridden and ambulatory, low baseline Hgb level 
and low baseline BMI were significantly associated with increased risk for acquiring TB 
in the study participants.  
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This study revealed that HIV infected individuals with Past TB history had 2.3 times high 
risk to develop TB as compared with HIV individuals with no have past TB history. Our 
finding was similar with findings from studies done in Israel and Malaysia and Uganda 
(16, 17, 38). The possible explanation could be due to poor compliance for their anti TB 
treatment at first episode and it could be due to relapse .Reactivation or re-infection 
might also possible with the existing dysregulated immunity. 
  
Participants not provided with IPT were 7 times higher risk to develop TB as compared 
to individuals who took IPT (AHR=6.96,95%2.53-19.08).This study found that  IPT were  
independent  risk factor associated with occurrence of incident TB among adult HIV 
patients. This is consistent with studies done in Ethiopia, South Africa and Brazil (24, 
34, 35). In fact, IPT is recommended to reduce and control TB among this group of 
people. Despite the fact, the poor uptake and the ambiguity and fear of drug resistance 
might contribute for these participants non- IPT user. This is an alarming to scale up the 
IPT on the setting.  
 
Patients’ ambulatory and bedridden functional status at baseline is 2.42 times more 
likely to develop TB in the entire follow up as compared to working functional status. 
This finding is in line with other study done in northwest Ethiopia(23).  The possible 
explanation was debilitated patients prone to malnutrition and less physical activity that 
make them prone for many diseases and TB. 
 
Patients with BMI of <18.5 at baseline was 1.62 times higher risk of developing TB as 
compared to adults with BMI≥18.5 at base line. This finding was consistent with phase 
III randomized controlled trial study done in Tanzania(30).It was also agrees with 
studies done in Ethiopia and south Africa (21, 40). The possible explanations, low BMI 
is a sign of malnutrition.HIV patients are prone for malnutrition. Malnutrition in HIV 
patients associated with increased catabolic activity, infection and loss of appetite and 
decreased in take. This all contributes for low BMI. Malnutrition is one of the pertinent 
risk factor of TB among HIV and non HIV patients.  
 
Similarly this study found that patients with Hgb level of <10 and 10-12.5 at base line  
were  2.00 and 2.54 times higher risk of developing TB than those having Hgb level 
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>12.5 at base line. Hematologic complications were risk factors for the incidence of TB 
among PLHIV .This finding was in line with studies conducted in Ethiopia, Uganda and 
Tanzania south Africa(30, 32, 33, 40). The Possible explanation is malnutrition and side 
effect of medications, opportunistic infections and advanced stage of the disease. 
Undiagnosed TB could explain the low Hgb level at the early enrollment. Variables like 
CD4 cell count and WHO clinical stage were not independently associated in this study.  
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6.  Strength of the study   
The study tried to include all possible variables that influences risk of TB among HIV 
patients that could accessed from the chart. The study was conducted for a five year 
follow up that helps to show the long term impact of HIV on TB. 
 
7.  Limitation of the study  
This study might have limitations that shared with limitation of most retrospective record 
based studies had. The retrospective and record based nature of the study design 
limited to include predictors that could affect the risk of TB like housing condition, house 
hold income and other. Due to incomplete data some study subjects were removed from 
the study that might undermine the finding if those study subjects had TB. The study not 
observed ART group and Pre ART group separately. 
 
  
37 
 
8. Conclusion  
The overall incidence of TB in the study setting is high.  HIV infected individuals with 
history of previous TB, not using IPT, base line BMI<18.5kg/m2, ambulatory and 
bedridden functional status and having baseline Hgb <12.5g/dl were most predictors of 
incident TB. 
9. Recommendation   
For governmental organizations and stakeholders: 
 
 Strengthen the TB /HIV collaborative activity   
 Giving trainings on the provision of IPT  that might Strengthen the strategies for 
prevention and control of TB among adult  HIV infected people  
 Close supervision for Implementation of the guidelines and standards strategies 
to prevent and control TB.   
 For health professionals: 
 Strength the provision of IPT and nutritional support to all eligible HIV individuals 
  Continuous follow up and early detection of malnutrition, prevention of other 
infection and  close monitoring for HIV patients enrolled with  ambulatory or 
bedridden functional status and low BMI <18.5and low Hgb at baseline  to 
control TB among this groups.  
 For patients  
 Patients would be encouraged to have improved treatment and care seeking and 
infection control behavior.  
For researchers:  
 Further prospective studies might need to include all factors that influence the 
risk of TB. 
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11. Annex 
 Annex-1 Information Sheet and Consent Form 
Title of the Research Project: Incidence and predictors of tuberculosis  among people 
living With HIV/AIDS in Dubti General Hospital , Asayta Hospital, Abala hospital , Awash 
and samara health centers, Afar region, Northeast Ethiopia, 2015. 
Name of Principal Investigator: Ausman Ahmed  
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Name of the Organization: University of Gondar, College of Medicine and Health 
Science, Department of Internal Medicine. 
Introduction   This information sheet is prepared for ARHO, Dubti General Hospital 
administration and Dubti hospital, Asayta  and Abala hospital chronic HIV care clinic 
focal person and the health centers.  The aim is to explain about the purpose of the 
study and the procedure of data collection. Moreover, to obtain permission and 
cooperation to done the research.  
Purpose of the Research Project: The study is aim to assess the incidence and 
predictors  among  adult people living with HIV/AIDS who enrolled in chronic HIV follow 
up clinic at Dubti General  Hospital ,Asayta hospital and three health centers   ,Afar 
region, Northeast Ethiopia, 2015. 
Risk and/or Discomfort: By participating in this research project no one patient will be 
harmed because the information is extracted from secondary data. Also, during data 
collection name or any unique patient identifying information will not recorded on the 
data collection format and the collected data will be kept confidential and security will be 
assured.  
Benefits: Participating in this research have no direct benefit for those individuals 
whose chart is included in the study but the indirect benefit is quite important for the 
participants ,other patients  and  for a community as a whole. This helps us in showing 
the appropriate action to pick up the determinants and to take a right measure in 
providing appropriate ways in strengthening the collaborative activities in TB/HIV care 
and treatment service provision. 
Incentives for Participating: data will be collected from patient charts and no need of 
providing any incentive to any one taking part in this study. 
Confidentiality: The information collected from the chart will kept confidential. The 
extracted information will not include unique patient identifying information or name. The 
data will be collected by trained professionals and confidentiality of information will 
secure safely and data will be stored in a file and locked with private password. Such 
information will not be revealed to anyone except the principal investigator.  
Person to contact: The research project will be reviewed and approved by the 
Institutional Review Board of College of Medicine and Health Sciences, University of 
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Gondar.  In case, if you want to know more information about the research and its 
undertakings, you can contact any one of the following persons through the address 
below.  
 
Ausman Ahmed 
Tell: 0910426480, E-mail:soyra3362@yahoo.com  
Mr. Melaku Kindie (BSc, MPH), University of Gondar, College of Medicine and 
Health Science, Institute of public health. 
Tel: 0913002871 
1. Dr. Desalew Mekonnen (MD, Assoc prof of Internal  medicine ), University of 
Gondar, College of Medicine and Health Science department of internal 
medicine. 
Tel:  
 
 
 
 
 
 
 
 
 
Annex 2:  English Questionnaire format  
Afar National Regional State, Dubti Hospital, Asayta hospital, Awash, Logia and 
Samara health centers  
             Data collection format  
         Activity and responsible body  Response 
Questionnaire Code  
Name of the health institutions   
Date of data collected  DD/MM/YYYY/        _____/_____/______ 
Name of Data Collector  
Supervisor Name Signature__________Date____________ 
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Ser 
.No 
Part I:socio demographic characteristics  Skip 
pattern  
 
101 
Date of enrollment  __/___/____   DD/MM/YY  
102 Age in years ____year  
103 Sex  1.Male     2.Female  
104 Level of education    1.No formal education  
  2.Primary   
  3.Secondary  
  4.More than secondary  
   5.Not recorded  
 
 
105 Residence  1.Urban      2.Rural  
106 Substance abuse 1.Khat    
2.Tobacco 
3.Alcohol       
4.Drugs 
5.not use 
 
   Part II:  HIV and Follow up related characteristics 
201 Did the patient had past TB 
history? 
1.Yes           3.not recorded 
2.No 
If #201 
is2 or 
3203 
202 Does the treatment completed? 1.yes          2.No  
203 Does the patient develop 
opportunistic infection (not TB) 
1.Yes (specify)____  
2.No  
 
204 What was  baseline Hgb level __________  
205 What was baseline BMI Height --------cm 
Weight _______kg 
BMI=w/h2_____ 
 
206 Does the patient has chronic 
illness  
1.yes (specify) ________ 
2.No 
 
207 Functional status of the patient  1.working  
2.Ambulatory  
3.Bed redden  
 
208 Baseline WHO clinical stage  1.I 
2.II 
3.III 
4.IV 
 
209 Baseline CD4 cell count  ___________  
Checked by Investigator: Signature _________Date ________ 
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            Part III:   Treatment  and Follow up related characteristics 
301 ART eligible date  __/__/__         DD/MM/YY  
302 Eligibility  criteria  1.CD4 cell count  
2.WHO clinical stage  
3.Both  
4.T-cell lymphocyte count 
 
303 Date ART started  __/____/_____ DD/MM/YY  
304 Initial regimen  1.d4t-3TC-NVP 
2.d4t-3TC-EFV 
3.AZT-3TC-NVP 
4.AZT-3TC-EFV 
5.TDF-3TC-EFV 
6.TDF-3TC-NVP 
7.ABC-3TC-NVP 
8.ABC-3TC-EFV 
 
305 Did the regimen changed? 1.yes      
 2.not yet 
3.Not recorded 
 
306 What was the reason for 
change? 
1.TB   
2.pregnancy   
3.side effect 
4.Failure  
5.Not recorded 
 
307 What was new regimen started? 1.d4t-3TC-NVP 
2.d4t-3TC-EFV 
3.AZT-3TC-NVP 
4.AZT-3TC-EFV 
5.TDF-3TC-EFV 
6.TDF-3TC-NVP 
7.ABC-3TC-NVP 
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8.ABC-3TC-EFV 
9.second line regimen  
308 Adherence status  1. consistent       
2. inconsistent   
 
309 Did the patient take CPT? 1.yes         
 2.No  
 
310 Did the patient take IPT? 1.Yes      
 2.No 
If 
no315 
411 Did the patient develop TB while 
she/he is on follow up  
1.yes 
2.no 
 
412 When was it developed? --/--/---      DD/MM/YY  
413 During what was it happen? 1.Pre-ART time 
2.On ART time 
 
414 What form of TB was it? 1.pulmunary (specify) 
2.Extra pulmonary  
3.Both 
4.MDR TB 
 
415 Last follow up date   ………. DD/MM/YY  
416 Status at last follow up 1.Alive        2.Transfer out 
3.Deid        4.Drop out   
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